New Study Shows Abbott's Novel Diagnostic Test has the Potential to Demonstrate Gold Standard Accuracy and Speed, Which Could Help Rule Out Heart Attacks Earlier at the Point of Care
ABBOTT PARK, Ill.,
More than seven billion diagnostic tests are run in the U.S. each year to help physicians make accurate, timely decisions about a person's medical treatment.2 Point-of-care diagnostic tests, that can often provide results within minutes, are used globally as hospitals face increased pressures to address overcrowding in emergency rooms and longer wait times. The goal of with-patient diagnostic tests is to deliver results with accuracy similar to the gold standard of high-sensitivity lab tests. The findings from the study indicate this new point-of-care blood test could help physicians streamline how patients are triaged in the emergency room by reducing the time it takes to rule out a heart attack and accelerating a safe discharge for low-risk patients– all with an accuracy comparable to a high sensitive cardiac troponin test used in a core-laboratory.
"The initial findings from this study indicate that, for a substantial proportion of patients, it may be possible to safely rule out heart attacks within 15 minutes of blood drawn in the emergency department," said
Researchers in
- Similar levels of accuracy between the two tests (area under the curve: 0.975 and 0.970 for the i-STAT TnI-Nx and hsTnI tests respectively).
- Similar abilities to rule out a heart attack using the Emergency Department Assessment of Chest Pain Score: 56.7 percent of patients were identified as low risk using i-STAT TnI-Nx, compared to 43.5 percent of patients using hsTnI test.
POTENTIAL FOR RAPID RULE-OUT, RIGHT AT THE POINT-OF-CARE
Troponin proteins are released from the heart and can be found at elevated levels in the blood when the heart muscle has been damaged due to lack of blood flow. The i-STAT® cardiac troponin test from Abbott has been used in hospitals globally to help aid the physician in diagnosing heart attacks, right at the patient's bedside. Abbott's newest point-of-care test, that was used in the research and is not yet commercially available, includes several enhancements, such as magnetic technology.
"When designing Abbott's newest point-of-care cardiac testing, we wanted to combine the benefits of higher-sensitivity troponin tests with the speed of results when it matters most," said
About the Study:
This analysis, published online on
ARCHITECT hsTnI is not available for use in the U.S.
i-STAT TnI-Nx product is in development and not available for sale.
i-STAT is a registered trademark of the Abbott group of companies in various jurisdictions.
For complete intended use and product information, visit www.pointofcare.abbott.
About Abbott:
At Abbott, we're committed to helping people live their best possible life through the power of health. For more than 125 years, we've brought new products and technologies to the world – in nutrition, diagnostics, medical devices and branded generic pharmaceuticals – that create more possibilities for more people at all stages of life. Today, 99,000 of us are working to help people live not just longer, but better, in the more than 150 countries we serve.
Connect with us at www.abbott.com, on
References:
- Pickering, JW et al. JAMA Cardiol. 2018; doi:10.1001/jamacardio.2018.3368
American Clinical Laboratory Association . Value of Lab Testing. Retrieved from: https://www.acla.com/value-of-lab-testing/
View original content to download multimedia:http://www.prnewswire.com/news-releases/new-study-shows-abbotts-novel-diagnostic-test-has-the-potential-to-demonstrate-gold-standard-accuracy-and-speed-which-could-help-rule-out-heart-attacks-earlier-at-the-point-of-care-300732901.html
SOURCE Abbott
Abbott Media: Aly Morici, (224) 668-0771; Abbott Financial: Lukas Szot, +1(224) 667-2299